Boston, MA, February 11, 2025 — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies announced today its latest strategic collaboration with Pfizer Inc., to develop a new platform that could enhance Pfizer’s ability to discover potent, specific, and …

2 天之前 · Pfizer and Alloy have collaborated on various antibody discovery efforts, including the use of Alloy's ATX-CLC platform. Launched in 2023 and accessible through Alloy's Antibody Discovery Services ...

1 天前 · Pfizer and Alloy have collaborated on various antibody discovery efforts, including the use of Alloy’s ATX-CLC platform. Launched in 2023 and accessible through Alloy’s Antibody Discovery Services unit, the ATX-CLC platform enables the expression of common light chain antibodies with full heavy chain diversity, thereby facilitating ...

1 天前 · Boston: Alloy Therapeutics Inc., a biotechnology ecosystem company has announced its latest strategic collaboration with Pfizer Inc., to develop a new platform. The new platform could enhance Pfizer’s ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery technologies.

1 天前 · Alloy will receive an undisclosed upfront payment from Pfizer and be eligible for pre-specified preclinical to commercial milestones on products originating on the platform. This is the latest in a string of partnership announcements for Alloy, with the company having announced collaborations with pharma majors Takeda (TYO: 4502) and Eli Lilly ...

Pfizer (NYSE:PFE) has entered into a multi-year collaboration with Alloy Therapeutics to develop a new antibody discovery platform. Under the deal, Alloy will receive an upfront payment from ...

1 天前 · Alloy Therapeutics announced Tuesday that it has deepened its strategic collaboration with Pfizer, for which the US company will develop a platform for discovering new types of antibodies. Under the terms of the agreement, the Boston-based biotech company will receive an upfront payment from the pharmaceutical giant, as well as milestone ...

1 天前 · The deal expands on an existing partnership between Pfizer and Alloy in which the pair worked together on a range of antibody discovery efforts and leveraged the biotech’s ATX-CLC platform. The ...

2 天之前 · )--Alloy Therapeutics Inc.（“Alloy”）是一家致力于使尖端药物发现技术民主化的生物技术生态系统公司，今天宣布与辉瑞公司（Pfizer Inc.）进行最新的战略合作，以开发一个新平台，增强辉瑞公司发现针对现有抗体发现技术难以解决的目标的有效，特异性和有效抗体 ...

Alloy Therapeutics has entered into a strategic collaboration with Pfizer to develop a platform designed to improve Pfizer’s capability to discover potent, specific, and effective antibodies for targets that are challenging to address with current antibody discovery technologies, including the use of Alloy’s ATX-Gx platform